Cancer Research Aziza Shad Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reszka, K. J.
Right arrow Articles by Burns, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reszka, K. J.
Right arrow Articles by Burns, C. P.
[Cancer Research 65, 6346-6353, July 15, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Inactivation of Anthracyclines by Cellular Peroxidase

Krzysztof J. Reszka1,3, Brett A. Wagner2, Lynn M. Teesch4, Bradley E. Britigan1,2,3, Douglas R. Spitz3 and C. Patrick Burns2

1 Research Service and Department of Internal Medicine, The Veterans Affairs Medical Center; Departments of 2 Medicine and 3 Radiation Oncology (Free Radical and Radiation Biology Graduate Program), and 4 Molecular Analysis Facility, Roy J. and Lucille A. Carver College of Medicine, and Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa

Requests for reprints: C. Patrick Burns, Department of Medicine, University of Iowa Hospitals, Iowa City, IA 52242. Phone: 319-356-2038; Fax: 319-353-8383; E-mail: c-burns{at}uiowa.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The anticancer anthracyclines, doxorubicin and daunorubicin, are highly cytotoxic to both cancer and normal cells. In this work, we have investigated the capacity of cellular myeloperoxidase to inactivate these agents. We show that incubation of human leukemia HL-60 cells with the anthracyclines in the presence of hydrogen peroxide and nitrite causes irreversible oxidation of the drugs, suggesting an extensive modification of their chromophores. Methimazole, 4-aminobenzoic acid hydrazide, or azide inhibits the reaction, suggesting that it is mediated by the cellular myeloperoxidase, an enzyme naturally present in large amounts in HL-60 cells. In contrast to the intact drugs, the oxidatively transformed anthracyclines were substantially less cytotoxic for HL-60 (assayed by apoptosis) and PC3 prostate cancer cells and H9c2 rat cardiac myoblasts in vitro (assayed by clonogenic survival), indicating that the oxidative metabolism of these agents leads to their inactivation. Using tandem mass spectrometry, we identified two specific metabolic products of the anthracycline degradation, 3-methoxyphthalic acid and 3-methoxysalicylic acid. These two metabolic products were obtained as authentic compounds and were nontoxic to HL-60 leukemic cells and cardiac myocytes. These findings may have important implications for the cellular pharmacology of anthracyclines and for clinical oncology.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The development of anthracycline resistance during chemotherapy has often been associated with the multidrug resistance pathways in which the net drug accumulation is decreased due to its efficient efflux, resulting in lower intracellular concentrations of the anthracycline and ultimately lower cytotoxicity. These processes are thought to be controlled by specific proteins (1–3).

Another mechanism that may affect efficacy of anthracycline chemotherapy is direct detoxification of the drugs because they can be actively metabolized into products with suppressed anticancer activity. Most mechanisms of anthracycline inactivation/detoxification have been associated with reductive mechanisms of drug metabolism (4). For instance, carbonyl reductase (EC 1.1.1.184), aldose reductase (EC 1.1.1.21), and dihydrodiol dehydrogenase 2 (EC 1.3/1.20), which may increase in anthracycline-resistant cell lines, convert daunorubicin to a less tumor active metabolite, daunorubicinol (13-hydroxydaunorubicin), by reduction of the keto group at carbon-13 (see chemical formula below, R: -H, daunorubicin; R: -OH, doxorubicin; ref. 5).

{04-2312fx01l}

Sublethal concentrations of daunorubicin can induce carbonyl reductases in pancreatic carcinoma cells (6) and may underlie a resistant phenotype. 13-Hydroxydaunorubicin, although a less potent antineoplastic agent, seems to be more cardiotoxic than its parent compound (6, 7) and readily accumulates in the heart.

An alternative reductive metabolism of anthracyclines, which engages NADPH-cytochrome P450 reductase, mitochondrial NADH dehydrogenase, or the reductase domain of endothelial nitric oxide synthase, converts the quinone moiety of the drugs to semiquinones and gives rise to reactive oxygen species via aerobic redox cycling (8–11). It is considered to be less important in killing cancer cells, although it is believed to play a role in the oxidative damage to the heart. This metabolism does not degrade the drugs so their redox active moiety remains unchanged, which renders them capable of generating continuous fluxes of reactive oxygen species for as long as the drugs remain in the body.

The only metabolic pathway that leads to degradation and permanent inactivation of anthracyclines known today is (per)oxidative metabolism (12–17). Many peroxidases such as horseradish peroxidase and lactoperoxidase (12, 17–20), as well as compounds with pseudoperoxidase activity such as microperoxidase (14), ferrylmyoglobin, and hemin (16), are capable of metabolizing anthracyclines in the presence of H2O2. This metabolism involves oxidation of the hydroquinone moieties of the drug, which leads to permanent loss of their characteristic absorption and fluorescent properties (13, 15). Nitrite, tyrosine, and acetaminophen markedly stimulate this peroxidative metabolism of anthracyclines (13, 17). Importantly, products of the oxidatively degraded anthracyclines are less toxic than their parent compounds (16, 21, 22). One such product, generated by ferrylmyoglobin oxidation of anthracyclines, has been identified as 3-methoxyphthalic acid (3-MePA; ref. 16). On the other hand, photosensitized oxidation forms 3-methoxysalicylic acid (3-MeSA; ref. 23). Formation of these species points out that oxidation of the anthracycline hydroquinone moiety causes a profound modification of the chromophore as both 3-MePA and 3-MeSA represent a residual D-ring species of the anthracycline skeleton. Importantly, 3-MePA has been detected not only in in vitro systems but also in the heart of mice treated with doxorubicin and in human myocardial biopsies exposed to the drug (16).

Because purified peroxidases catalyze oxidation of anthracyclines in the presence of H2O2 and nitrite (12–14, 17, 18), we also sought to determine if cellular-derived peroxidase(s) can support these reactions. In addition, we identified two major metabolites and examined their toxicity in cancer cell lines (HL-60 and PC3) and a normal cell line (H9c2). The characterization of these reactions may explain cellular, tissue, or organ sensitivity/resistance patterns to these particular anticancer antibiotics. A better understanding of these relationships and reactions have therapeutic implications as it may serve for manipulating drug toxicity in cancerous as well as normal tissues.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Chemicals. Doxorubicin, daunorubicin, sodium nitrite (99%+), methimazole, 4-aminobenzoic acid hydrazide, sodium azide, hydrogen peroxide (8.8 mol/L), catalase, and lactoperoxidase were obtained from Sigma Chemical Co. (St. Louis, MO). Myeloperoxidase (1 mg/mL stock solution), isolated from human neutrophils, was a generous gift from Dr. Jerrold Weiss (University of Iowa, Iowa City, IA). All other chemicals were of the highest purity available.

Cell culture. HL-60 cells were obtained from American Type Culture Collection (ATCC; Rockville, MD) and were maintained in RPMI 1640 containing 10% fetal bovine serum (FBS), and supplemented with 1.5 mmol/L L-glutamine, 76 units/mL penicillin, and 76 µg/mL streptomycin (Life Technologies, Inc., Grand Island, NY). Cells were grown in a humidified incubator at 37°C with 5% CO2. Cells in log growth phase were harvested by centrifugation and washed twice with fresh media or specified buffers. Cells were counted using a Coulter Model Zf cell counter (Coulter, Inc., Hialeah, FL) and the cell density adjusted to 1 x 106 cells/mL unless otherwise indicated.

The rat myoblast cell line H9c2 (2-1) was obtained from ATCC. The cells were grown in MEM supplemented with 1.5 mmol/L L-glutamine, 76 units/mL penicillin, and 76 µg/mL streptomycin with 10% FBS. Cells were passed before reaching confluence to maintain the myoblast phenotype and grown in a humidified incubator at 37°C with 5% CO2.

PC3 human prostate cancer cells were obtained from ATCC, and maintained in RPMI media supplemented with 10% FBS. Two days before experimentation, cells were plated into 60 mm Petri dishes and grown exponentially to 50% confluence. The Petri dishes containing cells were kept at 37°C in a humidified incubator with 5% CO2.

Oxidation of anthracyclines for the cytotoxicity assays in HL-60 and PC3 cells. To daunorubicin (50 µmol/L) in 50 mmol/L PBS (pH 7.0) was added 0.75 unit/mL lactoperoxidase followed by the addition of 1 mmol/L nitrite and 1 mmol/L H2O2 at room temperature. Within a few minutes, the sample was bleached, indicating that most of the drug was oxidized. This oxidation was verified by measuring absorbance at 480 nm. Then catalase (500 units/mL) was added and the samples were incubated for 1 hour to remove residual H2O2. As a control, lactoperoxidase (alone), H2O2 (alone), nitrite (alone), or their combination was added to cells in the absence of drug.

Apoptosis assay. HL-60 cells (500,000 cells/mL) were treated with daunorubicin (0, 10, 50, 100, 250, and 500 nmol/L) or oxidized daunorubicin at equivalent volumes. The cells were then incubated for 24 hours at 37°C in a humidified incubator with 5% CO2, after which they were harvested, washed, and processed for endonuclease DNA fragmentation assays as determined by DNA gel electrophoresis on 1% agarose gels and stained with ethidium bromide. Detailed procedures for this assay have been described (24, 25).

Clonogenic survival assay. Toxicity of intact and oxidized daunorubicin or doxorubicin was further evaluated by studying clonogenic survival of the PC3 prostate cancer cell and the H9c2 rat heart cardiomyocytes. For the PC3 studies, daunorubicin was oxidized with a lactoperoxidase/H2O2/NaNO2 system almost to completion as described above. Cells were then treated with an appropriate amount of intact or oxidized daunorubicin for 1 hour, after which the media was changed and toxicity was assayed by clonogenic survival (26). Briefly, for the clonogenic survival determination, cells were trypsinized, counted, and plated at several dilutions between 100 and 100,000 cells per 60 mm culture dish. After 2 weeks of incubation at 37°C, colonies were stained and counted. Data were normalized to sham-treated control plating efficiencies.

For the H9c2 cell study, doxorubicin was oxidized using HL-60 cells as the source of peroxidase. HL-60 cells at 106/mL in PBS (pH 7) were exposed to 20 µmol/L doxorubicin, and then 1 mmol/L nitrite and 1 mmol/L H2O2 were added. This was followed by 1-hour incubation at 37°C, during which most of the drug was oxidized. The drug in the presence of cells without nitrite and H2O2 additions served as the control. Before the drug exposure, H9c2 cells were trypsinized, washed, counted, and plated at 250, 500, or 1,000 cells/culture plate (15 x 60 mm) in MEM and 10% FBS supplemented with 1.5 mmol/L L-glutamine, 76 units/mL penicillin, and 76 µg/mL streptomycin (Life Technologies). Cells were allowed to attach for 24 hours as single cells in a humidified incubator at 37°C with 5% CO2. Then 0 to 1,000 nmol/L of parent doxorubicin and equivalent volumes of oxidized doxorubicin congener were added to H9c2 cells. The cultures were allowed to grow for 7 days with continuous drug exposure before fixing, staining, and clonogenic colony formation counts were made.

Spectrophotometric measurement. Oxidation of anthracyclines by isolated myeloperoxidase, HL-60 cells, H2O2, and nitrite was studied by measuring the absorption spectrum of the drugs in intervals using an Agilent Diode Array Spectrophotometer model 8453. Samples in 50 mmol/L PBS (pH 7.0) contained anthracycline, nitrite, and myeloperoxidase, and the reaction was initiated by the addition of a small aliquot of H2O2 (5 or 10 µL) as the last component. Time course measurements were carried out following changes in absorbance at 480 nm ({lambda}max for daunorubicin and doxorubicin). Data were collected at 2- or 5-second intervals during continuous stirring of the sample in a spectrophotometric cuvette (1 cm light path). The initial rate of oxidation, Vi, was determined from the initial linear portion of the A480 versus time traces using the method of linear regression. The initial concentration of drugs was kept low, ~10 µmol/L, to avoid their dimerization. All measurements were carried out at ambient room temperature of 22°C, and the experiments were repeated at least twice.

Metabolism of anthracyclines by HL-60 cells. Metabolism of anthracyclines by cellular myeloperoxidase was carried out by incubating the drugs with HL-60 cells either in PBS (pH 7.0), HBSS, RPMI 1640, or NaCl solution (0.9%), in the presence of H2O2 and nitrite (1 mmol/L each) at 37°C for 1 hour. At specific time points, aliquots of samples were centrifuged at 16,000 x g for 2 minutes and their absorption spectra were measured. Absorbance at 480 nm was then used to calculate the amount of drug remaining in the supernatants using {varepsilon}480 = 11,500 (mol/L)–1 cm–1 (27).

Synthesis of authentic 3-methoxyphthalic acid. 3-MePA was synthesized by the oxidation of 2,3-dimethylanisole while refluxing with excess KMnO4 in 70% water and 30% t-butyl alcohol (28). The synthesized material precipitated as white crystals with UV-Vis {lambda}max(H2O) near 300 nm, and produced a single TLC spot, which under UV visualization appeared blue. Nuclear magnetic resonance analysis in d6-DMSO showed a strong peak at 3.7 ppm attributed to OCH3, a doublet H1 at 7.4 ppm, a triplet H2 at 7.35 ppm, and a doublet H3 at 7.15 ppm. Additional mass spectroscopic (MS) analysis confirmed the product as being 3-MePA (as below). Authentic 3-MeSA and 6-MeSA were obtained from Sigma-Aldrich (St. Louis, MO).

Preparation of samples for mass spectrometry. To HL-60 cells at 1 x 106/mL in PBS (pH 7.0) was added 1 mmol/L NaNO2 and 50 to 100 µmol/L doxorubicin. Immediately, an aliquot was centrifuged free of cells and the supernatant frozen at –20°C. To the remaining sample was added 1 mmol/L H2O2 and incubated at 37°C. After the first hour of incubation, 1 x 106 HL-60 cells/mL, 1 mmol/L H2O2, and NaNO2 were added and allowed to incubate for 1 hour. Then the cells were removed by centrifugation and the supernatant frozen at –20°C. The samples were thawed and then filtered through 3,000 MW centrifugal filters (Millipore Corp., Bedford, MA).

Tandem mass spectrometry analysis of doxorubicin oxidation products. A Thermo Electron LCQ Deca ion trap mass spectrometer interfaced with a Surveyor liquid chromatograph and a photodiode array UV detector was used to analyze the samples by liquid chromatography (LC)-MS and tandem mass spectrometry (MS/MS). Samples were injected and separated on a 2.1 x 250 mm Vydac C-18 (5 µm) column (Grace Vydac218TP52) using a solvent system consisting of buffer A (0.1% formic acid in water) and buffer B (0.1% formic acid in acetonitrile). The LC gradient started at 10% Buffer B, then increased over 15 minutes to 70% Buffer B at a flow rate of 200 µL/min. The photodiode array UV detector was set to monitor both 315 and 480 nm for oxidized doxorubicin metabolites and for doxorubicin, respectively. Both positive and negative ion electrospray ionizations were used in the MS analysis. The (M + H)+ and (M – H)– ions of authentic doxorubicin and 3-MePA, respectively, were used to optimize the positive and negative MS variables. The mass spectrometer was set to alternate between collecting full scan MS and MS/MS data. For the full scan MS analysis, the spectra were collected over the range m/z 100 to 600. For the MS/MS analysis, the collision-induced decomposition (CID) energy was adjusted to 35% and the CID spectra were collected for each ion of interest based on its retention time determined during the LC-MS/MS analysis of the authentic compounds. For the negative ions of m/z 195 and 167, CID spectra were collected between 5.95 and 7.95 minutes and between 7.96 and 11.55 minutes, respectively. The positive ion CID spectra for m/z 544 were collected between 11.55 and 13.45 minutes.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Oxidation of anthracyclines by isolated myeloperoxidase. Here we show that metabolism of two anthracyclines by a myeloperoxidase system can be stimulated by nitrite, which is commonly found in micromolar quantities in serum. Figure 1A shows that when daunorubicin is exposed to myeloperoxidase, H2O2, and nitrite, its characteristic absorption band at 480 nm decreases, indicating that the drug has been oxidized. No such changes were observed when myeloperoxidase, H2O2, or nitrite was omitted. Figure 1A (top inset) shows the time course of A480 at various concentrations of nitrite and the effect of the sequential addition of H2O2, myeloperoxidase, and nitrite. It is apparent that the process depends on the simultaneous presence of all these reactants because no significant oxidation was observed when nitrite was omitted. In the studied nitrite concentration range, the initial rate, Vi, of the drug oxidation is linearly dependent on [nitrite] (Fig. 1A, bottom inset). This additionally shows the dependence of the drug metabolism by myeloperoxidase/H2O2 on the presence of nitrite. The reported concentrations of nitrite in biological fluids range up to 200 µmol/L (29, 30), which covers the initial portion of [nitrite] used in this study (Fig. 1A, bottom inset). Based on the data in Fig. 1A, the loss of daunorubicin has been determined to be 45.4, 72.8, 87.4, and 94.0% at [nitrite] = 100, 250, 500, and 1,000 µmol/L, respectively. When [nitrite] and [H2O2] were ~50 µmol/L, the maximal loss of the drug was 16%, although when nitrite was omitted the loss was only ~2.6% under otherwise identical conditions. The loss of drug absorption is irreversible, indicating profound changes in the drug chromophore. Similar results were obtained when daunorubicin was replaced by doxorubicin (not shown).



View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Oxidation of doxorubicin by myeloperoxidase/H2O2/nitrite systems in PBS (pH 7.0). A, absorption spectra recorded during daunorubicin (10.5 µmol/L) oxidation by isolated myeloperoxidase (93 nmol/L), H2O2 (265 µmol/L), and nitrite (500 µmol/L). Traces a to k were obtained at time 0, 20, 40, 60, 80, 100, 120, 140, 160, 220, and 260 seconds, respectively, after the start of the reaction (H2O2 addition) to a sample containing all other components. Top inset, time course of oxidation of daunorubicin followed by changes of absorption at 480 nm. Traces a to d were obtained at [NO2–] = 100, 250, 500, and 1,000 µmol/L, respectively. [H2O2] and [myeloperoxidase] the same as above. It is shown that in the absence of nitrite (NO2–), H2O2 and myeloperoxidase do not oxidize daunorubicin. Only when NO2– was added did the oxidation of daunorubicin become apparent. Bottom inset, initial rate of daunorubicin oxidation, Vi (= dA480 / dt) plotted versus [NaNO2]. B, absorption spectra resulting from oxidation of doxorubicin (16.5 µmol/L) by HL-60 cells (106 cells/mL) in the presence of H2O2 (1 mmol/L) and NO2– (1 mmol/L). Spectra shown are those measured after 0, 15, 30, and 60 minutes of incubation at 37°C. Inset, time course of A480 in the presence and absence of nitrite. Representative of two separate experiments.

 
Oxidation of anthracyclines by cellular peroxidase. The next experiment was designed to find out whether cellular myeloperoxidase is also capable of supporting anthracycline oxidation in the presence of H2O2 and nitrite. For this purpose, we used HL-60 cells, which naturally contain high concentrations of myeloperoxidase (24, 31). When HL-60 cells (1 x 106 cells/mL) were incubated in the presence of 16.6 µmol/L doxorubicin, 1 mmol/L nitrite, and 1 mmol/L H2O2 in PBS (pH 7.0), there was a gradual loss of absorption at 480 nm over 1 hour, although the biggest loss occurred during the first 30 minutes of the reaction (Fig. 1B). These changes are similar to those observed during the incubation of the drug with isolated myeloperoxidase (Fig. 1A). Fig. 1B (inset) illustrates the time course of A480 changes in the presence and absence of nitrite. Much less drug was lost when nitrite was omitted. When cells or H2O2 was omitted, none or very little drug has been lost (not shown). All these observations confirm that oxidation of the drug can also be accomplished by cellular myeloperoxidase. Also, loss of extracellular drug due to intracellular accumulation during 1-hour incubation was determined to be insignificant compared with extracellular drug loss in the presence of nitrite and H2O2 (data not shown).

The efficacy of the oxidation depends on the number of cells used (Fig. 2A). As little as 105 cells/mL sufficed to decrease daunorubicin concentration by 8.6 µmol/L or 43% during 1-hour incubation at 37°C in 0.9% NaCl solution. Doxorubicin was oxidized under the same conditions (results not shown).



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. A, oxidation of daunorubicin by myeloperoxidase-positive HL-60 cells: dependence on cell number. HL-60 cells were suspended in 0.9% NaCl at the densities shown and then treated with 20 µmol/L daunorubicin in the presence or absence of 1 mmol/L H2O2 and 1 mmol/L NaNO2 for 60 minutes at 37°C. Points, mean of three replicates; bars, SE. B, inactivation of doxorubicin by HL-60 cells (1 x 106/mL) in PBS (pH 7.0) with 1 mmol/L H2O2 and 1 mmol/L nitrite for 60 minutes at 37°C and the effect of peroxidase inhibitors. The peroxidase inhibitors methimazole (meth), 4-aminobenzoic acid hydrazide (ABAH), and azide (all at 1 mmol/L) were incubated with the cells for 15 minutes to inhibit peroxidase before the addition of doxorubicin (Dox), H2O2 (HP) and NaNO2 (N).

 
To confirm the involvement of cellular myeloperoxidase, in the next set of experiments we determined the effect of peroxidase inhibitors on doxorubicin oxidation. Cells treated with methimazole, 4-aminobenzoic acid hydrazide, or azide, all known inhibitors of peroxidases (32, 33), were unable to oxidize doxorubicin in the presence of H2O2 and nitrite (Fig. 2B). Similar inhibitory effects were observed for daunorubicin (17). This confirms that oxidation of anthracyclines by HL-60 cells involves their endogenous peroxidase.

Cytotoxicity of intact and oxidized anthracyclines in HL-60 cells. The human promyelocytic leukemia cell line HL-60 is sensitive to anthracyclines, which induce programmed cell death through apoptosis (24, 25, 34). To access whether oxidation of anthracyclines changes their toxicity profile, we did apoptosis assays in HL-60 cells exposed to the intact and oxidatively modified drug. Apoptosis was assessed by endonuclease DNA fragmentation. For these studies, daunorubicin was oxidized using purified lactoperoxidase in the presence of H2O2 and nitrite, as described earlier (13). It should be noted that following the drug oxidation, catalase (500 units/mL) was added and incubation was continued for 1 hour. This was to decompose unreacted H2O2 because our earlier study revealed that even low concentrations of the peroxide can induce apoptosis in this cell line (24). Following this, various aliquots of this reaction mixture and corresponding aliquots of the intact drug were added to HL-60 cells, which were then incubated for 24 hours at 37°C. As is shown in Fig. 3A, at concentrations of 10 to 100 nmol/L, intact daunorubicin induced apoptosis (lanes 3-5). At a higher concentration (250 nmol/L), the drug induced necrotic cell death (lane 6). In contrast, oxidized daunorubicin was unable to induce apoptosis when applied at 10 to 250 nmol/L (lanes 7-10). Also at 500 nmol/L, oxidized daunorubicin did not induce apoptosis or necrosis (not shown). These results indicate that the oxidized daunorubicin is markedly less cytotoxic than the intact drug. Control experiments showed that lactoperoxidase + H2O2 + nitrite without drug was nontoxic to HL-60 cells (Fig. 3A, lane 2). The results in Fig. 3A clearly establish that there is a loss in the apoptosis-inducing ability of oxidized daunorubicin.



View larger version (60K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Apoptosis gels. A, induction of apoptosis by untreated and oxidized daunorubicin in HL-60 cells determined by DNA fragmentation analysis. HL-60 cells were treated with daunorubicin (lanes 3-6) or oxidized daunorubicin (lanes 7-10), incubated for 24 hours, and genomic DNA was isolated, separated on a 1% agarose gel for 2.5 hours (2 µg DNA per lane), and stained with ethidium bromide. From left to right: lane 1, HL-60 cells, no treatment; lane 2, cells treated with the product(s) of lactoperoxidase + H2O2 + NO2–; lanes 3 to 6, cells treated with 10, 50, 100, and 250 nmol/L daunorubicin; lanes 7 to 10, cells treated with 10, 50, 100, and 250 nmol/L oxidized daunorubicin. The oxidized daunorubicin was prepared by addition of 0.75 unit/mL lactoperoxidase to a daunorubicin solution (50 µmol/L) in PBS (50 mmol/L, pH 7.0) containing 1 mmol/L H2O2 and 1 mmol/L NaNO2. Oxidation was completed in ~10 minutes after which catalase was added (50 µg/mL) to decompose unreacted H2O2, and incubation was continued for 1 hour. Then aliquots of the oxidized daunorubicin were added to HL-60. This gel shows that whereas daunorubicin alone is able to induce apoptosis in HL-60 cells (DNA laddering is clearly visible in lanes 3-5), the oxidized daunorubicin is not, under otherwise identical conditions. Representative of two experiments. B, lack of apoptosis of HL-60 leukemia cells induced by 3-MePA. HL-60 cells were exposed to 3-MePA at the four concentrations shown for 24 hours in full medium and apoptosis was determined. C, control cells not exposed to doxorubicin (DOX) or 3-MePA. STD, 100 bp standard.

 
Cytotoxicity in PC3 human prostate cancer cell line. Because anthracyclines are frequently used in the chemotherapy of prostate cancer, we examined the toxicity of oxidized daunorubicin in the PC3 human prostate adenocarcinoma cells. The PC3 cells were treated with intact and oxidized daunorubicin (0, 2, 10, and 50 µmol/L) for 1 hour and cell viability assayed as clonogenic survival using the method described (26). Results obtained show that oxidized daunorubicin is significantly less potent in killing the tumor cells than the intact drug. For example, following exposure to 10 µmol/L daunorubicin, the surviving fraction of cells was <5.7 x 10–5, whereas at the same concentration of oxidized drug, surviving fraction was 9.2 x 10–2 or more than three orders of magnitude higher. This indicates that oxidation of daunorubicin dramatically suppresses its cytotoxic properties in this cell line.

Cytotoxicity in cardiac myocyte H9c2 cell line. In the experiments described above, we compared cytotoxicity of intact and oxidized daunorubicin in two types of cancer cells. It was of interest to find out whether oxidation of daunorubicin decreases its toxicity for normal cells. For this purpose, we chose the rat heart myoblast cell line H9c2, which is known to be sensitive to anthracyclines (16, 35–37). Because cardiotoxicity is the major side effect of anthracycline chemotherapy, investigation of the oxidation of the drugs on their toxicity in these cells is relevant. We assessed changes in clonogenic survival of H9c2 cells treated with intact and oxidized doxorubicin.

In this set of experiments, we used doxorubicin oxidized by HL-60 cells (as the peroxidase source), H2O2, and nitrite (1 mmol/L each), as described above. As Fig. 4 shows, doxorubicin at concentrations less than 10 nmol/L caused a substantial decrease in clonogenic survival of H9c2 cells; in this case, less than 6% at 10 nmol/L, with 50% of the cells dead between 2.5 and 5 nmol/L. In contrast, the oxidized drug in the same concentration range showed minimal toxicity. It took at least 500 nmol/L of the oxidized drug to cause a 5% survival (not shown). Given these data, the approximate dose modification factor is ~50, indicating that the oxidatively modified doxorubicin has significantly reduced toxicity also in this cell line. This change in toxicity is probably a conservative estimate because some residual unreacted doxorubicin could be still present in the oxidized samples and probably contributed to the cell death observed.



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Clonogenic survival of H9c2 cardiac myoblasts. Doxorubicin at 20 µmol/L was added to PBS (pH 7) with 1 x 106/mL HL-60 cells with or without H2O2 and nitrite (1 mmol/L each) to obtain inactivated and active doxorubicin at comparable concentrations, respectively. After 1-hour incubation at 37°C, the HL-60 cells were removed by centrifugation and the cell-free media was treated with catalase before the concentration of drug was measured by spectrophotometry at 480 nm. Aliquots of the resultant supernatant with the inactivated and active anthracycline were then added to previously plated singly attached H9c2 cells. After 7 days, the media was removed, the cells fixed, stained, and counted for clonogenic survival.

 
Identification of inactivation metabolites. LC-MS and MS/MS studies were done to identify the degradation products of doxorubicin. In these experiments, parent drug decreased to 5% to 20% of the starting concentration of ~100 µmol/L. The UV chromatograms of the untreated and inactivated drug were monitored at both 315 nm (Fig. 5) and 480 nm (not shown). Figure 5 shows that with treatment, a peak at 11.7 minutes (corresponding to authentic doxorubicin) remarkably decreases, and a new peak at 6.8 minutes appears.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. The UV chromatograms from the LC-MS analysis of the HL-60–mediated oxidized and untreated samples. The UV detector was set at 315 nm for both samples.

 
The (M + H)+ ion for doxorubicin (m/z 544) is observed in the mass spectrum at 11.7 minutes in the untreated sample, along with fragment ions of m/z 397 (aglycone), 379 (aglycone–H2O), 361 (aglycone–2 H2O), and 321 (aglycone-side chain–H2O). This is in agreement with earlier reports (38, 39). The CID of the (M + H)+ ion of authentic doxorubicin produces two major ions, m/z 397 and 379 (not shown).

In the chromatogram of the inactivated sample, the peak at 6.8 minutes, not present in the untreated sample, is consistent with the retention time of authentic 3-MePA. The negative ion LC-MS results were also consistent with a previous identification of this compound (16). The (M – H)– ion of m/z 195 was observed for the authentic 3-MePA and in the mass spectrum at 6.8 minutes in the inactivated sample (Fig. 6, left). The fragment ion of m/z 151 due to the loss of CO2 is also observed in both LC-MS and CID spectra. The CID spectra of both the 3-MePA standard and the oxidized sample are similar in that the only product ion observed is m/z 151. Therefore, we believe this degradation product can be identified as 3-MePA based on the LC-MS and MS-MS data presented.



View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. MS analysis of the HL-60–mediated oxidized doxorubicin. Included are the negative ion electrospray full scan mass spectra (bottom) and CID tandem mass spectra (top) for (M – H)– ions of m/z 195 and 167. These spectra are from the data corresponding to the retention times of 3-MePA at 6.8 minutes (left) and 3-MeSA at 9.6 to 9.8 minutes (right).

 
The authentic 3-MeSA was detected on our LC-MS system as a peak at 9.6 minutes when monitored at 315 nm. When the HL-60–mediated oxidized samples were analyzed by LC, there was no detectable UV peak at 9 to 10 minutes that would correspond with 3-MeSA. However, when selectively looking for ions of m/z 167 in the MS data, a signal at 9.6 to 9.8 minutes was revealed. The CID spectrum of m/z 167 at this retention time shows product ion of m/z 152 attributable to 3-MeSA after loss of methyl group. Other minor ions, of m/z 123 (loss of CO2) and m/z 108 (loss of methyl and CO2), were also detected (Fig. 6, right). The similar retention times as well as the similar fragment ions, when compared with authentic 3-MeSA, are consistent with small amounts of 3-MeSA being present in oxidized doxorubicin samples.

Lack of toxicity of authentic 3-methoxyphthalic acid and 3-methoxysalicylic acid. We determined the toxicity of authentic 3-MePA and 3-MeSA toward HL-60 cells and H9c2 cardiac myocytes. No evidence of toxicity measured by apoptosis in HL-60 cells treated with 3-MePA and 3-MeSA, up to 10 µmol/L, was found. Figure 3B shows the results with 3-MePA at 100, 500, 1,000, or 10,000 nmol/L and distinct banding with 250 nmol/L doxorubicin. In addition, we studied the toxicity of these metabolites in H9c2 cells using clonogenic assay. They seem to be nontoxic. At the highest concentration of authentic 3-MePA or 3-MeSA (10 µmol/L), the clonogenic survival was 101.7 ± 4.7% for 3-MePA and 114.7 ± 9.8% for 3-MeSA.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Our experimental results show that cell-derived myeloperoxidase can oxidize anthracyclines in the presence of H2O2 and nitrite. Most importantly, the products of this oxidative modification of daunorubicin and doxorubicin are substantially less cytotoxic compared with their parent drugs. The loss of anthracycline toxicity was shown by the oxidized drugs possessing markedly suppressed capacity to induce apoptosis (HL-60) and causing higher clonogenic survival in neoplastic (PC3) and nonneoplastic (H9c2) heart cell lines.

Our earlier study showed that in the presence of nitrite, myeloperoxidase/H2O2 oxidizes the hydroquinone moiety of doxorubicin to a semiquinone radical (Eq. A; ref. 13). Although the exact mechanism of the nitrite stimulatory action is not known, we hypothesize that the .NO2 radical, a product of the oxidation of NO2– by myeloperoxidase/H2O2 (18, 40, 41), could be involved. .NO2 is a powerful oxidant and could react with the hydroquinone moiety of the drug, causing its oxidation (13).

(1)
where Q-QH2 and Q-QH. are the quinone-hydroquinone moiety of the drug and the corresponding semiquinone radical, respectively, and MPO is myeloperoxidase.

Another possibility is that NO2– accelerates the conversion of the less reactive forms of the enzyme (myeloperoxidase compounds II and III) accumulating during the reaction back to native enzyme. Both these actions should result in a more efficient oxidation of the anthracyclines. Nitrite is present in vivo, primarily as a result of dietary intake as well as the end product of oxidation of .NO. Small amounts of .NO are produced during normal cellular functions but its biosynthesis is markedly intensified in response to infections and during inflammatory conditions usually associated with cancer. Therefore, colocalization of nitrite with peroxidase systems and anthracyclines in the vicinity of cancer is likely. Interestingly, it has been shown that doxorubicin itself stimulates the biosynthesis of nitrite in both normal cells (H9c2 cardiac myocytes) and in cancer cells (EMT-6 breast cancer cell line; refs. 42, 43).

Although the exact molecular mechanism through which anthracyclines undergo oxidation has not been fully elucidated, it seems certain that it involves the hydroquinone moiety of the drug (ring B, formula in Introduction; refs. 13, 14, 17). In contrast to radicals formed by metabolic reduction (8–11), the radicals formed by oxidation, Q-QH., do not react with O2, but rather disproportionate to the parent compound and the highly electrophilic diquinone (2 Q-QH. -> Q-QH2 + Q-Q). The diquinone may undergo further transformation to stable products with modified chromophores. Thus, oxidation of the hydroquinone moiety of the drugs is the first step on the pathway to their degradation.

Using MS, we have identified 3-MePA and 3-MeSA as metabolic products of the leukemic cell peroxidase-induced oxidation of doxorubicin. 3-MePA is the more abundant product and is the same compound that results from the oxidative degradation of doxorubicin by ferrylmyoglobin (16). 3-MeSA was previously identified when doxorubicin was oxidized by photoactivated riboflavin (23). Most importantly, authentic chemical preparations of the two compounds failed to manifest toxicity against leukemic or nonneoplastic heart cells. This lack of toxicity explains the inactivation of the parent drug doxorubicin by oxidation.

Concentrations of doxorubicin, H2O2, and nitrite used in some experiments are substantially higher than their physiologic or therapeutic concentrations. This was, however, dictated by the need to obtain metabolites at amounts sufficient for subsequent analysis and to overcome the catalase activity of the cells. At therapeutic doses, the concentration of anthracyclines in the blood is submicromolar, which should require less peroxide and nitrite for their oxidation. Under inflammatory conditions, usually associated with cancer, local concentrations of myeloperoxidase, peroxide, and nitrite may be markedly elevated due to higher activity of neutrophils and macrophages. Due to low concentrations of reactants and the presence of alternative targets, the peroxidative metabolism of anthracyclines in tissues may be significantly slower than that in our in vitro systems. We speculate, however, that because the process may occur over a prolonged period of time, it still may be responsible for inactivation of a part of the administered drug.

Although data on biological activities of oxidized anthracyclines are scarce, two recent studies have reported that doxorubicin oxidized by horseradish peroxidase/H2O2 inhibits creatine kinase and succinate dehydrogenase, two enzymes important for the proper function of the heart (19, 20). Another study has shown that photodegraded doxorubicin was much less effective in inhibiting growth of P388 murine leukemia cells compared with nonirradiated compound (21). Finally, a recent study by Cartoni et al. (16) showed that 3-MePA, the major product of the metabolism of anthracyclines by myoglobin/H2O2, is markedly less cytotoxic for the H9c2 rat cardiac myocytes than nonoxidized drug. Results of our cytotoxicity studies using the H9c2 cell line agree with this report.

The use of many chemotherapeutics is limited due to toxicity to organs such as heart, liver, kidneys, as well as bone marrow. Besides poor tumor response, in some instances other complications such as drug resistance may develop during the course of treatment that may cause clonal expansion with cross-resistance to other chemotherapeutic drugs. Therefore, strategies aimed at enhancing target cell sensitivity, preventing drug resistance, as well as suppressing toxicity to nontarget cells, tissues, or organs, become especially important with the current generation of drugs. In this respect, we believe that we have addressed a new and unrecognized pathway by which leukemic cells, as well as other cancers that express peroxidases, may potentially inactivate anthracyclines in vivo and decrease the efficacy of the anthracycline therapy.

We conclude that peroxidase contained in human leukemia cells is capable of inactivating anthracycline anticancer drugs especially in the presence of an additional peroxidase substrate such as nitrite. It is important to emphasize that nitrite is not the only cofactor capable of stimulating the process, as many phenolic compounds, including tyrosine and acetaminophen, exert a similar prooxidant activity (17, 44). In addition, given that cellular antioxidants ascorbic acid and reduced glutathione, as well as peroxidase blockers, inhibit oxidative degradation of anthracyclines by myeloperoxidase and HL-60 cells (17), it seems that inactivation of the drugs in vivo could be modulated by pharmacologic interventions. This inactivation may affect cellular pharmacology of anthracyclines and have implications to clinical oncology.


   Acknowledgments
 
Grant support: Grants P01 CA66081 (C.P. Burns) and R01 CA100045 (D.R. Spitz) awarded by the National Cancer Institute; R01 AI 34954 (B.E. Britigan) awarded by the National Institute of Allergy and Infectious Diseases, Department of Health and Human Services; grant 0256079Z (K.J. Reszka) awarded by the Heartland Affiliate of the American Heart Association; Merit Award from the VA Research Service (B.E. Britigan); The Dr. Richard O. Emmons Memorial Fund; The Mamie C. Hopkins Fund; and The Iowa Leukemia and Cancer Research Fund.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank The University of Iowa college of Medicine Nuclear Magnetic Resonance Facility (William Kearney, PhD, Director) and Ling Li for her helpful assistance with the clonogenic survival assay of PC3 cells.

Received 6/30/04. Revised 4/26/05. Accepted 5/ 3/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938–46.[Abstract/Free Full Text]
  2. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340–58.[CrossRef][Medline]
  3. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461:237–62.[Medline]
  4. Licata S, Saponiero A, Mordente A, Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 2000;13:414–20.[CrossRef][Medline]
  5. Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000;59:293–300.[CrossRef][Medline]
  6. Soldan M, Netter KJ, Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem Pharmacol 1996;51:117–23.[Medline]
  7. Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001;52:83–8.[CrossRef][Medline]
  8. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A 1979;76:954–7.[Abstract/Free Full Text]
  9. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986;261:3060–7.[Abstract/Free Full Text]
  10. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727–41.[CrossRef][Medline]
  11. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (Adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47:219–31.[CrossRef][Medline]
  12. Kolodziejczyk P, Reszka K, Lown JW. Enzymatic oxidative activation of 5-iminodaunorubicin. Spectrophotometric and electron paramagnetic resonance studies. Biochem Pharmacol 1989;38:803–9.[Medline]
  13. Reszka KJ, McCormick ML, Britigan BE. Peroxidase- and nitrite-dependent metabolism of the anthracycline anticancer agents daunorubicin and doxorubicin. Biochemistry 2001;40:15349–61.[CrossRef][Medline]
  14. Reszka KJ, McCormick ML, Britigan BE. Oxidation of anthracycline anticancer agents by the peroxidase mimic microperoxidase 11 and hydrogen peroxide. Free Radic Biol Med 2003;35:78–93.[CrossRef][Medline]
  15. Menna P, Salvatorelli E, Giampietro R, et al. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Chem Res Toxicol 2002;15:1179–89.[CrossRef][Medline]
  16. Cartoni A, Menna P, Salvatorelli E, et al. Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin. J Biol Chem 2004;279:5088–99.[Abstract/Free Full Text]
  17. Reszka KJ, Britigan LH, Rasmussen GT, Wagner BA, Burns CP, Britigan BE. Acetaminophen stimulates the peroxidative metabolism of anthracyclines. Arch Biochem Biophys 2004;427:16–29.[CrossRef][Medline]
  18. Reszka KJ, Matuszak Z, Chignell CF, Dillon J. Oxidation of biological electron donors and antioxidants by a reactive lactoperoxidase metabolite from nitrite (NO2–): an EPR and spin trapping study. Free Radic Biol Med 1999;26:669–78.[CrossRef][Medline]
  19. Muraoka S, Miura T. Inactivation of mitochondrial succinate dehydrogenase by Adriamycin activated by horseradish peroxidase and hydrogen peroxide. Chem Biol Interact 2003;145:67–75.[Medline]
  20. Miura T, Muraoka S, Fujimoto Y. Inactivation of creatine kinase by Adriamycin during interaction with horseradish peroxidase. Biochem Pharmacol 2000;60:95–9.[CrossRef][Medline]
  21. Bomgaars L, Gunawardena S, Kelley SE, Ramu A. The inactivation of doxorubicin by long ultraviolet light. Cancer Chemother Pharmacol 1997;40:506–12.[Medline]
  22. Reszka KJ, Britigan LH, McCormick ML, Britigan BE, Spitz DR. Do pain killers counteract the anticancer action of anthracyclines? In: 2nd International Conference on Prostate Cancer Research; 2002; Iowa City, IA; 2002.
  23. Ramu A, Mehta MM, Liu J, Turyan I, Aleksic A. The riboflavin-mediated photooxidation of doxorubicin. Cancer Chemother Pharmacol 2000;46:449–58.[CrossRef][Medline]
  24. Wagner BA, Buettner GR, Oberley LW, Darby CJ, Burns CP. Myeloperoxidase is involved in H2O2-induced apoptosis of HL-60 human leukemia cells. J Biol Chem 2000;275:22461–9.[Abstract/Free Full Text]
  25. Wagner BA, Britigan BE, Reszka KJ, McCormick ML, Burns CP. Hydrogen peroxide-induced apoptosis of HL-60 human leukemia cells is mediated by the oxidants hypochlorous acid and chloramines. Arch Biochem Biophys 2002;401:223–34.[CrossRef][Medline]
  26. Spitz DR, Malcolm RR, Roberts RJ. Cytotoxicity and metabolism of 4-hydroxy-2-nonenal and 2-nonenal in H2O2-resistant cell lines. Do aldehydic by-products of lipid peroxidation contribute to oxidative stress? Biochem J 1990;267:453–9.[Medline]
  27. Chaires JB, Dattagupta N, Crothers DM. Self-association of daunomycin. Biochemistry 1982;21:3927–32.[Medline]
  28. Wentzel BB, Donners MPJ, Alsters PL, Feiters MC, Nolte RJM. N-hydroxyphthalimide/cobalt(II) catalyzed low temperture benzylic oxidation using molecular oxygen. Tetrahedron 2000;56:7797–803.[CrossRef]
  29. Gaston B, Reilly J, Drazen JM, et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A 1993;90:10957–61.[Abstract/Free Full Text]
  30. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131–8.[CrossRef][Medline]
  31. Nauseef WM. Myeloperoxidase biosynthesis by a human promyelocytic leukemia cell line: insight into myeloperoxidase deficiency. Blood 1986;67:865–72.[Abstract/Free Full Text]
  32. Klebanoff SJ. Myeloperoxidase: Occurrence and biological function. In: Everse J, Everse KE, Grisham MB, editors. Peroxidases in chemistry and biology. Boca Raton: CRC Press; 1991. p. 1–35.
  33. Kettle AJ, Gedye CA, Winterbourn CC. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem J 1997;321:503–8.
  34. Wagner BA, Reszka KJ, McCormick ML, Britigan BE, Evig CB, Burns CP. Role of thiocyanate, bromide and hypobromous acid in hydrogen peroxide-induced apoptosis. Free Radic Res 2004;38:167–75.[Medline]
  35. DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, Butterfield DA. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 1999;134:51–62.[CrossRef][Medline]
  36. DeAtley SM, Aksenov MY, Aksenova MV, et al. Antioxidants protect against reactive oxygen species associated with Adriamycin-treated cardiomyocytes. Cancer Lett 1999;136:41–6.[CrossRef][Medline]
  37. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 1999;368:421–8.[CrossRef][Medline]
  38. Bloom J, Lehman P, Israel M, Rosario O, Korfmacher WA. Mass spectral characterization of three anthracycline antibiotics: a comparison of thermospray mass spectrometry to particle beam mass spectrometry. J Anal Toxicol 1992;16:223–7.[Medline]
  39. Lachatre F, Marquet P, Ragot S, Gaulier JM, Cardot P, Dupuy JL. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;738:281–91.[Medline]
  40. Bruck TB, Fielding RJ, Symons MC, Harvey PJ. Mechanism of nitrite-stimulated catalysis by lactoperoxidase. Eur J Biochem 2001;268:3214–22.[Medline]
  41. Burner U, Furtmuller PG, Kettle AJ, Koppenol WH, Obinger C. Mechanism of reaction of myeloperoxidase with nitrite. J Biol Chem 2000;275:20597–601.[Abstract/Free Full Text]
  42. Aldieri E, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl Pharmacol 2002;185:85–90.[CrossRef][Medline]
  43. Lind DS, Kontaridis MI, Edwards PD, Josephs MD, Moldawer LL, Copeland EM III. Nitric oxide contributes to Adriamycin's antitumor effect. J Surg Res 1997;69:283–7.[CrossRef][Medline]
  44. Reszka KJ, McCormick ML, Britigan BE. Tyrosine and ABTS enhance and ascorbate and cysteine inhibit the peroxidative metabolism of anthracyclines. Free Rad Biol Med 2001;31:S140.



This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
P. Menna, E. Salvatorelli, and G. Minotti
Doxorubicin Degradation in Cardiomyocytes
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 408 - 419.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. J. Reszka, L. H. Britigan, and B. E. Britigan
Oxidation of Anthracyclines by Peroxidase Metabolites of Salicylic Acid
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 283 - 290.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reszka, K. J.
Right arrow Articles by Burns, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reszka, K. J.
Right arrow Articles by Burns, C. P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online